IQ EQ FUND MANAGEMENT IRELAND Ltd Buys 4,504 Shares of Personalis, Inc. (NASDAQ:PSNL)

IQ EQ FUND MANAGEMENT IRELAND Ltd grew its stake in shares of Personalis, Inc. (NASDAQ:PSNL) by 42.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,103 shares of the company’s stock after buying an additional 4,504 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd’s holdings in Personalis were worth $81,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of PSNL. Acadian Asset Management LLC increased its position in shares of Personalis by 6.7% in the second quarter. Acadian Asset Management LLC now owns 1,057,956 shares of the company’s stock worth $1,237,000 after purchasing an additional 66,128 shares during the last quarter. ARK Investment Management LLC boosted its stake in Personalis by 4.9% in the second quarter. ARK Investment Management LLC now owns 6,361,886 shares of the company’s stock worth $7,443,000 after buying an additional 296,413 shares in the last quarter. Virtu Financial LLC purchased a new stake in Personalis in the first quarter worth approximately $41,000. Jacobs Levy Equity Management Inc. boosted its stake in Personalis by 144.7% in the first quarter. Jacobs Levy Equity Management Inc. now owns 821,657 shares of the company’s stock worth $1,224,000 after buying an additional 485,822 shares in the last quarter. Finally, Public Employees Retirement System of Ohio purchased a new stake in Personalis in the first quarter worth approximately $29,000. 61.91% of the stock is currently owned by institutional investors.

Personalis Stock Up 5.4 %

Shares of Personalis stock opened at $4.87 on Friday. The company has a market cap of $258.50 million, a PE ratio of -2.97 and a beta of 1.92. The business has a 50 day moving average of $5.29 and a 200 day moving average of $2.96. Personalis, Inc. has a 52 week low of $0.89 and a 52 week high of $7.20.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.10. The business had revenue of $22.58 million during the quarter, compared to the consensus estimate of $19.81 million. Personalis had a negative return on equity of 56.87% and a negative net margin of 101.78%. During the same quarter in the prior year, the company earned ($0.50) earnings per share. On average, research analysts anticipate that Personalis, Inc. will post -1.15 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. HC Wainwright increased their price objective on Personalis from $7.50 to $9.00 and gave the company a “buy” rating in a research note on Monday, August 19th. Needham & Company LLC increased their price objective on Personalis from $5.50 to $7.25 and gave the company a “buy” rating in a research note on Friday, August 16th. Finally, BTIG Research increased their price objective on Personalis from $5.50 to $7.00 and gave the company a “buy” rating in a research note on Friday, August 16th.

Personalis Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.